Company intelligence / Profile preview

Origenis GmbH

Planegg/Martinsried near Munich, Bavaria, Germanyorigenis.de ↗
Ownership
Private
Employees
~30
Development stage
Preclinical
01

Overview

Origenis has developed a robust AI-driven platform for small molecule drug discovery with a focus on neurodegenerative and neuroinflammatory diseases. Its lead programs have been spun out into Neuron23 Inc., which has raised over $113 million to advance these assets toward clinical trials. The company continues to innovate in CNS, oncology, antiviral, and ophthalmology pipelines but does not yet have late-stage or commercialized products.

Therapeutic areas
OncologyImmunologyNeurology
Modalities
small molecules
Industry
Biotech
02

Drug pipeline

1 asset

ORI-15412

Preclinical
03

Partnerships

Alcon (ophthalmology)Probiodrug/Vivoryon (CNS)Mestrelab Research SL (software collaboration)Kleiner Perkins & Westlake Village BioPartners et al. through partnership/spin-out with Neuron23 Inc.

Beyond the preview

Go deeper on Origenis GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Origenis GmbH.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call